基石药业（苏州）有限公司 CSTONE PHARMACEUTICALS
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
CStone received IND approval in China for HDAC6 inhibitor CS3003 2019-03-13 10:10
CStone Pharmaceuticals listed on the Hong Kong Stock Exchange today 2019-02-27 10:47
Avapritinib receives Phase III clinical trial approval for GIST in China 2019-02-15 23:19
CStone and IMPACT Therapeutics' clinical collaboration progresses to IND filing acceptance for CS1001+IMP4297 combination therapy 2019-02-08 03:10
CStone receives CTA approval in China to start Phase I trial for FGFR4 inhibitor BLU-554 (CS3008) 2019-01-29 10:19
CStone Pharmaceuticals announces initiation of CS1001 Phase I Study in U.S., patient enrollment under way 2018-12-21 17:50
CStone Pharmaceuticals Appoints Former MSD Global Oncology Early Development Executive Director Archie Tse, M.D., Ph.D., as the newly established SVP, Chief Translation Medicine Officer 2018-12-10 15:38
CStone initiates a bridging Phase I clinical trial for PD-1 antibody CS1003 with first patient dosed in China 2018-11-19 12:54
CStone announces first patient dosed in Phase I study in China for MEK inhibitor CS3006 2018-10-30 10:28
CStone Receives US FDA IND Approval for Recombinant PD-1 mAb CS1003 2018-10-24 10:08
CStone Receives U.S. IND Approval for PD-L1 Antibody CS1001 2018-10-16 16:48
CStone's Anti-CTLA-4 Antibody CS1002 Receives IND Approval in China 2018-08-28 10:16
CStone's MEK Inhibitor CS3006 Receives IND Approval in China 2018-07-30 12:51
CStone's PD-1 inhibitor CS1003 receives clinical trial approval in China 2018-07-12 12:45
CStone enrolls first patient in Phase I study for MEK inhibitor CS3006 in Australia 2018-06-20 19:07
CStone Pharmaceuticals Initiates Two Pivotal Phase II Studies of the Anti-PD-L1 Monoclonal Antibody CS1001 2018-06-13 15:09
CStone announces first patient dosing with anti-PD-1 antibody CS1003 in Phase I study in Australia 2018-05-14 18:36
CStone Raises $260 million in Series B Financing to Advance Novel Cancer Therapies 2018-05-09 11:18
CStone announces first patient dosed with anti-CTLA-4 antibody CS1002 of a Phase I study in Australia 2018-05-04 14:47
CStone's anti-CTLA-4 antibody CS1002 filed for clinical trial approval in Australia 2017-12-29 21:00
1 4 5 6 7 8